165 related articles for article (PubMed ID: 35834073)
1. Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells.
O'Grady S; Crown J; Duffy MJ
Med Oncol; 2022 Jul; 39(10):142. PubMed ID: 35834073
[TBL] [Abstract][Full Text] [Related]
2. Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
Smoots SG; Schreiber AR; Jackson MM; Bagby SM; Dominguez ATA; Dus ED; Binns CA; MacBeth M; Whitty PA; Diamond JR; Pitts TM
Breast Cancer Res; 2024 Mar; 26(1):35. PubMed ID: 38429789
[TBL] [Abstract][Full Text] [Related]
3. Enhanced therapeutic efficacy of doxorubicin/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells.
Dewidar SA; Hamdy O; Soliman MM; El Gayar AM; El-Mesery M
Med Oncol; 2023 Dec; 41(1):7. PubMed ID: 38051378
[TBL] [Abstract][Full Text] [Related]
4. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
[TBL] [Abstract][Full Text] [Related]
5. Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.
Jung HH; Lee SH; Kim JY; Ahn JS; Park YH; Im YH
Sci Rep; 2016 Sep; 6():33035. PubMed ID: 27604655
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 murine oviductal epithelial cells induce progression of high-grade serous carcinoma and are most sensitive to simvastatin therapy in vitro and in vivo.
Pereira M; Glogova A; Haagsma J; Stewart J; Shepherd TG; Petrik J
J Ovarian Res; 2023 Nov; 16(1):218. PubMed ID: 37986175
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
Synnott NC; Bauer MR; Madden S; Murray A; Klinger R; O'Donovan N; O'Connor D; Gallagher WM; Crown J; Fersht AR; Duffy MJ
Cancer Lett; 2018 Feb; 414():99-106. PubMed ID: 29069577
[TBL] [Abstract][Full Text] [Related]
8. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
[TBL] [Abstract][Full Text] [Related]
9. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells.
Synnott NC; O'Connell D; Crown J; Duffy MJ
Breast Cancer Res Treat; 2020 Jan; 179(1):47-56. PubMed ID: 31538264
[TBL] [Abstract][Full Text] [Related]
10. PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis.
Zaza M; Rashed MH; Elrefaey H; Hassan MH; Abo-Salem OM; El-Sayed ESM
Can J Physiol Pharmacol; 2024 Jan; 102(1):55-68. PubMed ID: 37818839
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK.
Koyuturk M; Ersoz M; Altiok N
Cancer Lett; 2007 Jun; 250(2):220-8. PubMed ID: 17125918
[TBL] [Abstract][Full Text] [Related]
12. MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975.
Tang M; O'Grady S; Crown J; Duffy MJ
Breast Cancer Res Treat; 2022 Sep; 195(2):105-115. PubMed ID: 35908121
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a.
Wolfe AR; Debeb BG; Lacerda L; Larson R; Bambhroliya A; Huang X; Bertucci F; Finetti P; Birnbaum D; Van Laere S; Diagaradjan P; Ruffell B; Trenton NJ; Chu K; Hittelman W; Diehl M; Levental I; Ueno NT; Woodward WA
Breast Cancer Res Treat; 2015 Dec; 154(3):495-508. PubMed ID: 26590814
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin induces breast cancer cell death through oxidative stress up-regulating miR-140-5p.
Bai F; Yu Z; Gao X; Gong J; Fan L; Liu F
Aging (Albany NY); 2019 May; 11(10):3198-3219. PubMed ID: 31138773
[TBL] [Abstract][Full Text] [Related]
15. Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome c.
Ghavami S; Mutawe MM; Hauff K; Stelmack GL; Schaafsma D; Sharma P; McNeill KD; Hynes TS; Kung SK; Unruh H; Klonisch T; Hatch GM; Los M; Halayko AJ
Biochim Biophys Acta; 2010 Apr; 1803(4):452-67. PubMed ID: 20045437
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin and atorvastatin as inhibitors of proliferation and inducers of apoptosis in human cholangiocarcinoma cells.
Buranrat B; Senggunprai L; Prawan A; Kukongviriyapan V
Life Sci; 2016 May; 153():41-9. PubMed ID: 27098189
[TBL] [Abstract][Full Text] [Related]
17. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.
Jabbour-Leung NA; Chen X; Bui T; Jiang Y; Yang D; Vijayaraghavan S; McArthur MJ; Hunt KK; Keyomarsi K
Mol Cancer Ther; 2016 Apr; 15(4):593-607. PubMed ID: 26826118
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
Wang ZT; Chen ZJ; Jiang GM; Wu YM; Liu T; Yi YM; Zeng J; Du J; Wang HS
Cell Signal; 2016 May; 28(5):506-515. PubMed ID: 26876786
[TBL] [Abstract][Full Text] [Related]
19. Kruppel-like factor 2 mediated anti-proliferative and anti-metastasis effects of simvastatin in p53 mutant colon cancer.
Lu L; Huang W; Hu W; Jiang L; Li Y; Wu X; Yuan D; Li M
Biochem Biophys Res Commun; 2019 Apr; 511(4):772-779. PubMed ID: 30833076
[TBL] [Abstract][Full Text] [Related]
20. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]